Cargando…
Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis
BACKGROUND: With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of Leishmania donovani is vital to preserve it and support the V...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358331/ https://www.ncbi.nlm.nih.gov/pubmed/22629478 http://dx.doi.org/10.1371/journal.pntd.0001657 |
_version_ | 1782233777193353216 |
---|---|
author | Bhandari, Vasundhra Kulshrestha, Arpita Deep, Deepak Kumar Stark, Olivia Prajapati, Vijay Kumar Ramesh, V. Sundar, Shyam Schonian, Gabriele Dujardin, Jean Claude Salotra, Poonam |
author_facet | Bhandari, Vasundhra Kulshrestha, Arpita Deep, Deepak Kumar Stark, Olivia Prajapati, Vijay Kumar Ramesh, V. Sundar, Shyam Schonian, Gabriele Dujardin, Jean Claude Salotra, Poonam |
author_sort | Bhandari, Vasundhra |
collection | PubMed |
description | BACKGROUND: With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of Leishmania donovani is vital to preserve it and support the VL elimination program. METHODOLOGY AND PRINCIPAL FINDINGS: We measured in vitro susceptibility towards MIL and paromomycin (PMM) in L. donovani isolated from VL and PKDL, pre- and post-treatment cases, using an amastigote-macrophage model. MIL susceptibility of post-treatment isolates from cured VL cases (n = 13, mean IC(50)±SD = 2.43±1.44 µM), was comparable (p>0.05) whereas that from relapses (n = 3, mean IC(50) = 4.72±1.99 µM) was significantly higher (p = 0.04) to that of the pre-treatment group (n = 6, mean IC(50) = 1.86±0.75 µM). In PKDL, post-treatment isolates (n = 3, mean IC(50) = 16.13±2.64 µM) exhibited significantly lower susceptibility (p = 0.03) than pre-treatment isolates (n = 5, mean IC(50) = 8.63±0.94 µM). Overall, PKDL isolates (n = 8, mean IC(50) = 11.45±4.19 µM) exhibited significantly higher tolerance (p<0.0001) to MIL than VL isolates (n = 22, mean IC(50) = 2.58±1.58 µM). Point mutations in the miltefosine transporter (LdMT) and its beta subunit (LdRos3) genes previously reported in parasites with experimentally induced MIL resistance were not present in the clinical isolates. Further, the mRNA expression profile of these genes was comparable in the pre- and post-treatment isolates. Parasite isolates from VL and PKDL cases were uniformly susceptible to PMM with respective mean IC(50) = 7.05±2.24 µM and 6.18±1.51 µM. CONCLUSION: The in vitro susceptibility of VL isolates remained unchanged at the end of MIL treatment; however, isolates from relapsed VL and PKDL cases had lower susceptibility than the pre-treatment isolates. PKDL isolates were more tolerant towards MIL in comparison with VL isolates. All parasite isolates were uniformly susceptible to PMM. Mutations in the LdMT and LdRos3 genes as well as changes in the expression of these genes previously correlated with experimental resistance to MIL could not be verified for the field isolates. |
format | Online Article Text |
id | pubmed-3358331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-33583312012-05-24 Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis Bhandari, Vasundhra Kulshrestha, Arpita Deep, Deepak Kumar Stark, Olivia Prajapati, Vijay Kumar Ramesh, V. Sundar, Shyam Schonian, Gabriele Dujardin, Jean Claude Salotra, Poonam PLoS Negl Trop Dis Research Article BACKGROUND: With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy. Surveillance of MIL susceptibility in natural populations of Leishmania donovani is vital to preserve it and support the VL elimination program. METHODOLOGY AND PRINCIPAL FINDINGS: We measured in vitro susceptibility towards MIL and paromomycin (PMM) in L. donovani isolated from VL and PKDL, pre- and post-treatment cases, using an amastigote-macrophage model. MIL susceptibility of post-treatment isolates from cured VL cases (n = 13, mean IC(50)±SD = 2.43±1.44 µM), was comparable (p>0.05) whereas that from relapses (n = 3, mean IC(50) = 4.72±1.99 µM) was significantly higher (p = 0.04) to that of the pre-treatment group (n = 6, mean IC(50) = 1.86±0.75 µM). In PKDL, post-treatment isolates (n = 3, mean IC(50) = 16.13±2.64 µM) exhibited significantly lower susceptibility (p = 0.03) than pre-treatment isolates (n = 5, mean IC(50) = 8.63±0.94 µM). Overall, PKDL isolates (n = 8, mean IC(50) = 11.45±4.19 µM) exhibited significantly higher tolerance (p<0.0001) to MIL than VL isolates (n = 22, mean IC(50) = 2.58±1.58 µM). Point mutations in the miltefosine transporter (LdMT) and its beta subunit (LdRos3) genes previously reported in parasites with experimentally induced MIL resistance were not present in the clinical isolates. Further, the mRNA expression profile of these genes was comparable in the pre- and post-treatment isolates. Parasite isolates from VL and PKDL cases were uniformly susceptible to PMM with respective mean IC(50) = 7.05±2.24 µM and 6.18±1.51 µM. CONCLUSION: The in vitro susceptibility of VL isolates remained unchanged at the end of MIL treatment; however, isolates from relapsed VL and PKDL cases had lower susceptibility than the pre-treatment isolates. PKDL isolates were more tolerant towards MIL in comparison with VL isolates. All parasite isolates were uniformly susceptible to PMM. Mutations in the LdMT and LdRos3 genes as well as changes in the expression of these genes previously correlated with experimental resistance to MIL could not be verified for the field isolates. Public Library of Science 2012-05-22 /pmc/articles/PMC3358331/ /pubmed/22629478 http://dx.doi.org/10.1371/journal.pntd.0001657 Text en Bhandari et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Bhandari, Vasundhra Kulshrestha, Arpita Deep, Deepak Kumar Stark, Olivia Prajapati, Vijay Kumar Ramesh, V. Sundar, Shyam Schonian, Gabriele Dujardin, Jean Claude Salotra, Poonam Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis |
title | Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis |
title_full | Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis |
title_fullStr | Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis |
title_full_unstemmed | Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis |
title_short | Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis |
title_sort | drug susceptibility in leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358331/ https://www.ncbi.nlm.nih.gov/pubmed/22629478 http://dx.doi.org/10.1371/journal.pntd.0001657 |
work_keys_str_mv | AT bhandarivasundhra drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT kulshresthaarpita drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT deepdeepakkumar drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT starkolivia drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT prajapativijaykumar drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT rameshv drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT sundarshyam drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT schoniangabriele drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT dujardinjeanclaude drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis AT salotrapoonam drugsusceptibilityinleishmaniaisolatesfollowingmiltefosinetreatmentincasesofvisceralleishmaniasisandpostkalaazardermalleishmaniasis |